Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
The Japan Pharmaceutical Manufacturers Association (JPMA) unveiled its fresh proposal on August 30, calling for introducing a new value-based pricing system for innovative medicines and excluding patent-protected drugs from the current market price-based NHI price revisions. The outline of the…
To read the full story
Related Article
- JPMA Chief Calls for Prompt Price Cuts for LLPs, Generic Industry Consolidation
February 17, 2023
- JPMA Now Finalizing Policy Proposal 2023, Due Out “before Cherry Blossoms”
January 20, 2023
- JPMA to Present Proposal on Value-Based Drug Pricing at Upcoming Panel Hearing
September 16, 2022
- FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
- FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
- JPMA Urges Govt to Expand Support to Boost Competitiveness of Japan Pharma Industry
August 31, 2022
ORGANIZATION
- Japanese Drug Makers Step Up Use of ASEAN Reliance Reviews
June 18, 2026
- Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
- Raise Foreign Price Adjustment Cap for Listed Products in German Cases: FPMAJ
June 15, 2026
- FPMAJ Seeks Predictability in Price Maintenance System for Innovative Medicines
June 15, 2026
- LLP Extra Patient Charge Influences Generic Adoption at Over 40% of Hospitals: FPMAJ
June 15, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…